title: Medical treatment after peripheral bypass surgery over the past decade.
abstract: OBJECTIVE
  The Dutch Bypass and Oral anticoagulants or Aspirin (BOA) Study demonstrated that in patients with peripheral arterial disease after bypass surgery oral anticoagulants were more effective in preventing venous graft occlusions than aspirin, while aspirin was more effective in non-venous grafts. We evaluated if this finding was implemented in the clinical practice of former BOA participants by reconstructing a 10-year overview of their applied various drug treatments including anti-hypertensive and lipid-lowering drugs.
  
  
  METHODS
  In 482 patients from six centers that contributed most patients anti-thrombotic, anti-hypertensive, and lipid-lowering drug use was recorded at baseline (n = 478), retrospectively up to two years after BOA (n = 388), and prospectively for patients still alive between 2005 and 2009 (n = 209).
  
  
  RESULTS
  At baseline, 54% of patients received anti-thrombotics which increased to 96% at follow-up. At baseline 15% of patients were treated with lipid-lowering drugs and 49% with anti-hypertensives. This increased over time to 65% and 76%, respectively.
  
  
  CONCLUSIONS
  After the BOA Study its recommendations were applied marginally. Despite improvements over time, current lipid-lowering and anti-hypertensive drug use remained suboptimal. Our trend analyses, however, should be interpreted with caution, because drug use and compliance in survivors might be better than average.
authors.affiliation: Department of Vascular Surgery (G.04.129), University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The Netherlands. evhattum@tsz.nl
authors.forename: E S
authors.initials: ES
authors.lastname: van Hattum
authors.forename: M J D
authors.initials: MJ
authors.lastname: Tangelder
authors.forename: M A
authors.initials: MA
authors.lastname: Huis in 't Veld
authors.forename: J A
authors.initials: JA
authors.lastname: Lawson
authors.forename: A
authors.initials: A
authors.lastname: Algra
authors.forename: F L
authors.initials: FL
authors.lastname: Moll
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000627:therapeutic use; D015331:Cohort Studies; D005260:Female; D006083:Graft Occlusion, Vascular / Q000453:epidemiology / Q000517:prevention & control*; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009426:Netherlands; D058729:Peripheral Arterial Disease / Q000150:complications / Q000188:drug therapy / Q000601:surgery*; D011182:Postoperative Care; D012189:Retrospective Studies; D016896:Treatment Outcome; D058017:Vascular Grafting
chemical_list: D000925:Anticoagulants; D000959:Antihypertensive Agents; D000960:Hypolipidemic Agents